Defense Secretary Pete Hegseth announced on July 15, 2026, that all active-duty military service members aged 30 and older will be required to undergo annual testosterone screening as part of their routine health assessments, with those found to have low testosterone levels given the option to receive testosterone replacement therapy. The initiative, which Hegseth described in a video titled "The High T Department of War," is framed as a readiness and optimization measure, aimed at ensuring that service members have the right testosterone levels to operate at their absolute best.
Medical experts, including urologists, endocrinologists, and military health researchers, responded within days, raising concerns that the announcement understated or omitted the documented side effects of testosterone replacement therapy, particularly for younger service members who may want to have children.
Why This Matters
Testosterone replacement therapy has legitimate clinical applications. Men with documented hypogonadism, confirmed by two morning testosterone measurements below established thresholds, along with symptoms including low libido, fatigue, decreased muscle mass, and depression, can benefit meaningfully from treatment. The American Urological Association and Endocrine Society have established evidence-based protocols for identifying and treating true testosterone deficiency.
What both of those clinical guidelines explicitly recommend against is population-level screening of asymptomatic men. The Endocrine Society's current guidance specifically advises against routine testosterone screening in the general population, including younger men with low testosterone in the absence of symptoms, because the evidence does not support broad screening benefits and because treatment in men without confirmed clinical deficiency carries risks without established benefit.
The Pentagon's mandate applies to all service members over 30 regardless of symptoms, which is precisely the screening model that current clinical guidelines do not support.
What We Know So Far
Hegseth's July 15 announcement, posted on his X account and accompanied by a Pentagon statement, described the policy as designed to identify testosterone deficiency, which can undermine health, and to offer service members the choice to pursue treatment. The announcement described the initiative as restoring and optimizing natural capabilities rather than artificial enhancement, and as protecting longevity.
The Pentagon told TIME magazine that it had no additional information beyond Hegseth's video and the department statement. No clinical protocol, no criteria for defining testosterone deficiency in this context, and no safety monitoring framework was described in the public announcement.
As of July 15, Hegseth had not specified whether female service members would also be screened, or whether the policy included women, who represent approximately 17 percent of the active-duty force and for whom off-label testosterone therapy raises different clinical considerations.
Where the Impact Is Highest
The impact falls most directly on active-duty male service members aged 30 to 40, a group in the prime reproductive years for whom testosterone therapy's documented effect on sperm production and fertility is clinically significant. According to Politifact's medical review, once external testosterone is introduced, the body suppresses its own production. Because the body needs its own testosterone to produce sperm, external therapy can reduce sperm counts and cause testicular atrophy, effects that are often reversible but are not guaranteed to be so in every patient.
Service members at installations without robust endocrinology or urology support may have less access to the monitoring that responsible testosterone therapy requires, creating disparities in how safely the program is implemented across military health facilities.
What Doctors and Experts Say
"There's no free lunch. There are side effects," said Dr. Jeff Morrison, a urologist at the University of Colorado, in TIME magazine. "If you are interested in further fertility, then TRT is probably not a good option." Morrison noted that he specifically counsels younger men in their 30s and 40s about the fertility implications before initiating therapy.
A urologist who has conducted DOD-funded studies on testosterone use in military beneficiaries wrote in a STAT News op-ed that data from those studies found higher rates of kidney stones and obstructive sleep apnea in military beneficiaries who used testosterone supplementation. The author noted that both the American Urological Association and Endocrine Society guidelines caution against testosterone usage in men who plan to have children due to fertility impact, and warned: "I fear that the widespread rollout of testosterone screening may lead to some surprising and unintended consequences."
CNBC's medical coverage cited an endocrinology specialist who noted that low testosterone levels naturally result from a range of reversible conditions, including sleep apnea, thyroid disease, and obesity, and that addressing the underlying cause rather than supplementing testosterone directly is the clinically appropriate first approach for most men.
What the Evidence Shows and What It Does Not
Testosterone replacement therapy has a well-established evidence base for men with confirmed symptomatic hypogonadism. A major 2023 clinical trial, the largest and most comprehensive to date, found no higher rate of heart attack, stroke, or cardiovascular death among men receiving testosterone therapy compared to placebo. However, the same trial identified higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the treatment group, findings that underscore the need for patient selection and monitoring. The evidence does not support population-level testosterone screening of asymptomatic men, which is the direct recommendation of current Endocrine Society guidelines. The documented side effects of testosterone therapy include fertility impairment through sperm suppression, worsening of pre-existing sleep apnea, elevated red blood cell counts that increase thrombosis risk, acne, breast tissue growth, mood changes, and skin reactions. These side effects are documented in the medical literature and were not addressed in the Pentagon's announcement. What the announcement did not specify is a diagnostic threshold, a monitoring protocol, a safety surveillance mechanism, or a framework for informed consent addressing fertility and other risks.
Who Faces the Greatest Risk
Service members most at risk from the side effects described by physicians are those in their 30s who have not yet had children and may plan to do so, as testosterone therapy can reduce fertility, sometimes temporarily and sometimes with more lasting effects. Service members with undiagnosed sleep apnea, which is common in the military population, face worsening of that condition with testosterone use. Those with high baseline hematocrit, who would face elevated thrombosis risk from further red blood cell stimulation, and those with pre-existing prostate disease also require medical screening before testosterone therapy that the announcement did not address.
Symptoms and Warning Signs to Watch For
Service members who begin testosterone therapy should be monitored regularly for symptoms of polycythemia, the elevated red blood cell count that testosterone stimulates, including headaches, visual disturbances, flushing, and unusual fatigue that may signal elevated hematocrit. Worsening snoring, disrupted sleep, or partner reports of breathing pauses during sleep should be evaluated as possible exacerbation of sleep apnea. Any new or worsening breast tissue development, significant acne, or mood changes should also be brought to a physician's attention promptly.
What You Can Do Now
Military service members and their families should not feel pressured to begin testosterone therapy without a thorough individual clinical evaluation. Before accepting therapy under the new screening program, service members should ask their military health provider about their specific testosterone level, what the diagnostic threshold for treatment is in their case, whether underlying treatable causes of low testosterone have been evaluated, what the specific fertility implications are for their reproductive plans, and what monitoring will be in place if they begin treatment.
Active-duty members concerned about the policy can consult a military medical officer or request a referral to endocrinology or urology within the TRICARE system. The American Urological Association's patient information resources are available at auanet.org.
Cost and Access: What Patients Should Know
Testosterone replacement therapy through TRICARE, the military health insurance system, is covered for medically indicated treatment. The new screening program is being integrated into existing periodic health assessments, meaning the screening itself will not carry an out-of-pocket cost. However, the monitoring required for safe testosterone use, including regular blood tests for hematocrit, prostate-specific antigen, and testosterone levels, and follow-up consultations, adds to the overall health system resource commitment of the program.
What Happens Next
Military health researchers and urologists are calling for a clearly defined clinical protocol before widespread implementation, including a diagnostic threshold, a monitoring framework, and documentation of how fertility counseling will be provided to affected service members. Congressional oversight committees may request additional information from the Pentagon about the clinical basis for the policy. MedicalDaily will track both the implementation of the program and the clinical and legislative responses as they develop.
The Bottom Line
Testosterone replacement therapy is a well-established treatment for confirmed, symptomatic hypogonadism. It is not without meaningful side effects, and current clinical guidelines from the American Urological Association and Endocrine Society specifically recommend against the population-level screening of asymptomatic men that the Pentagon has now mandated. Infertility risk is the concern most directly relevant to younger service members, and physicians say it was absent from the Pentagon's announcement. Service members subject to this policy deserve the full informed consent discussion that the medical guidelines require.
